How Nanotechnology Could Solve Dermatology’s Biggest Delivery Problem

By Dr. Noopur JainReviewed by Susha Cheriyedath, M.Sc.May 25 2026

From nano-sunscreens to smart drug carriers, a new review shows how tiny particles could improve skin care and treatment, but only if researchers can overcome safety, stability, and regulatory hurdles.

Narrative Review: Nanotechnology in Dermatology: A Comprehensive Narrative Review of Performance, Safety, and Clinical Translation. Image Credit: marevgenna / Shutterstock

In a recent review article published in the journal Health Science Reports, researchers comprehensively examined the performance, safety, and clinical translation challenges of nanotechnology applications in dermatology. The article was a narrative review, not a meta-analysis, and quantitative pooling was not performed because study designs, endpoints, and evidence types were highly heterogeneous.

Nanotechnology in Dermatology Overview

At the nanoscale (1–100 nm), materials often exhibit unique physicochemical properties that can be harnessed to enhance the bioavailability, stability, and targeting of active agents used in skin therapies. In dermatology, nanoparticles can support more controlled, localized, epidermal, follicular, or transdermal delivery of drugs and protective agents, depending on particle type, formulation, and skin condition, which has driven the rise of nano-enabled cosmeceuticals and therapeutics.

Common nanomaterials include metallic nanoparticles such as titanium dioxide (TiO₂), zinc oxide (ZnO), silver (Ag), and gold (Au); polymeric nanoparticles formed from biocompatible polymers like PLGA and chitosan; and lipid-based systems like solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and liposomes.

Each class offers distinct advantages and challenges: metallic nanoparticles provide antimicrobial and photoprotective effects but may pose cytotoxicity risks at higher doses and with certain surface chemistries; polymeric nanoparticles afford controlled drug release and generally improved biocompatibility; and lipid-based carriers improve skin barrier function and reduce irritation in inflammatory diseases such as atopic dermatitis.

However, factors such as formulation instability, oxidative degradation, and batch variability continue to hinder the reliable scaling of these technologies for clinical use. Moreover, safety data, especially regarding long-term systemic exposure, remain insufficient, with varied results on nanoparticle penetration through intact versus damaged skin. The review also cautioned that clinical superiority over optimized conventional formulations has not been consistently demonstrated.

Regulatory frameworks differ substantially worldwide, with the European Union emphasizing pre-market notification and nano-labeling requirements, while the U.S. adopts a more manufacturer-driven risk assessment approach. The lack of harmonized standards complicates the safe introduction of nanotechnology-based dermatologic products.

Key Nanocarrier Findings

The authors synthesized findings from 128 studies spanning preclinical and early clinical research. Metallic nanoparticles like TiO₂ and ZnO have generally shown minimal systemic absorption when applied to intact skin, retaining primarily within the epidermis, which supports their continued use in sunscreens.

Nevertheless, silver nanoparticles exhibit dose-dependent cytotoxicity, linked to reactive oxygen species generation and membrane disruption, raising concerns, especially in wound-healing applications where higher local concentrations may accumulate.

Polymeric nanoparticles, such as those based on PLGA and chitosan, have been evaluated for diseases like psoriasis and acne due to their ability to mediate sustained, localized drug delivery, which may improve local delivery and reduce systemic exposure in early studies.

Lipid-based carriers have shown promise in inflammatory skin conditions by enhancing skin hydration and barrier restoration while reducing irritation, as demonstrated in clinical formulations containing tacrolimus or ceramide-cholesterol mixtures for atopic dermatitis.

Nanocarriers have also improved follicular targeting in alopecia treatments and antimicrobial efficacy in chronic wounds. Innovations in stimuli-responsive nanoparticles that release drugs in response to environmental triggers and exosome-based delivery systems derived from plants or cells hold potential, though clinical validation of these newer modalities remains in early stages.

Translational Challenges and Insights

The review highlights the multifaceted benefits of nanotechnology in dermatology, principally related to enhanced bioavailability, targeted delivery, and potentially reduced irritation or systemic exposure in selected applications compared to conventional formulations.

Yet, translational hurdles remain considerable. The heterogeneous nature of experimental designs across studies, varying particle characteristics, skin models, application methods, and outcome measures, complicates direct comparisons and meta-analyses.

Moreover, formulation challenges, including nanoparticle stability under physiological conditions and the risk of microbial contamination, require robust manufacturing and quality control strategies. Safety concerns are paramount; while many nanomaterials like TiO₂ and ZnO present minimal systemic exposure in intact skin models, silver nanoparticles represent a cautionary example where toxicity thresholds and environmental risks necessitate strict concentration controls.

The review highlights gaps in long-term safety data and the need for physiologically relevant toxicity models, such as organ-on-chip platforms, to better simulate human skin interactions. Regulatory heterogeneity, with non-uniform definitions and approval pathways for nanotechnology in dermatology products, hampers clinical translation and patient confidence.

Nevertheless, emerging technologies such as stimuli-responsive nanocarriers and exosome-based therapies offer exciting prospects for precision and regenerative medicine approaches in skin care. The deployment of Artificial Intelligence">AI-driven formulation optimization and wearable diagnostic patches represents a transformative trend toward personalized, adaptive dermatology.

Future Directions and Implications

Nanotechnology holds transformative potential in dermatology by enabling improved therapeutic outcomes through enhanced drug delivery, photoprotection, and skin barrier repair. Metallic, polymeric, and lipid-based nanoparticles each offer unique functional benefits for a spectrum of skin conditions, from inflammatory diseases to wounds and photoaging, with safety profiles that vary by material, dose, coating, formulation, and skin-barrier status.

However, clinical adoption is constrained by formulation instability, inconsistent research methodologies, regulatory variability, and insufficient long-term safety data. Metal oxide UV filters such as TiO₂ and ZnO are currently the most clinically established nano-dermatology applications, whereas many polymeric, lipid-based, exosome, and stimuli-responsive systems remain preclinical or in early clinical trials. Addressing these critical gaps through standardized characterization methods, advanced toxicity models, and harmonized international regulatory frameworks is essential.

The integration of cutting-edge technologies, such as AI-personalized nanocarriers, exosome-based therapies, and smart wearable devices, may accelerate the development and clinical translation of safe, effective nano-dermatological interventions.

Coordinated efforts among researchers, manufacturers, regulators, and clinicians will be pivotal in unlocking the full potential of nanotechnology to potentially improve outcomes for patients with chronic skin disorders, provided safety, manufacturing, and regulatory barriers are addressed.

Download your PDF copy by clicking here.